Y-mAbs Faces Delay In Pediatric Neuroblastoma With Refuse-To-File Letter

 
• By Joseph Haas
  
FDASignBldg21Entrance_1200x675
An FDA refuse-to-file letter will delay review of Y-mAbs' omburtamab
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D